Abiopharma

🔍 Klinger Shannon Thyme (Executive)

Company: Moderna, Inc. (MRNA)

Report Date: 2025-08-27

Detailed Transactions and Holdings:

• Acquired 774 shares of Common Stock (Direct)
  Date: 2025-08-27 | Code: M | equity_swap_involved: 0 | shares_owned_after: 28,257.00 | transaction_form_type: 4 | Footnotes: F1, F1
• Sold 375 shares of Common Stock at $24.73 per share (Direct)
  Date: 2025-08-27 | Code: F | equity_swap_involved: 0 | shares_owned_after: 27,882.00 | transaction_form_type: 4 | Footnotes: F2
• Acquired 329 shares of Common Stock (Direct)
  Date: 2025-08-28 | Code: M | equity_swap_involved: 0 | shares_owned_after: 28,211.00 | transaction_form_type: 4 | Footnotes: F1, F1
• Sold 160 shares of Common Stock at $25.1 per share (Direct)
  Date: 2025-08-28 | Code: F | equity_swap_involved: 0 | shares_owned_after: 28,051.00 | transaction_form_type: 4 | Footnotes: F2
• Sold 774 shares of Restricted Stock Units (Derivative)
  Date: 2025-08-27 | Code: M | equity_swap_involved: 0 | shares_owned_after: 7,736.00 | transaction_form_type: 4 | Footnotes: F1, F1, F3, F3
• Sold 329 shares of Restricted Stock Units (Derivative)
  Date: 2025-08-28 | Code: M | equity_swap_involved: 0 | shares_owned_after: 1,973.00 | transaction_form_type: 4 | Footnotes: F1, F1, F4, F4

Footnotes:

• F1: Restricted stock units convert into common stock on a one-for-one basis.
• F2: Represents shares withheld at the election of the Reporting Person to satisfy tax withholding obligations in connection with the vest of restricted stock units.
• F3: 25% of the shares subject to this restricted stock unit award vested on February 27, 2025 with the remainder vesting in twelve (12) equal quarterly installments thereafter.
• F4: 25% of the shares subject to this restricted stock unit award vested on February 28, 2024 with the remainder vesting in twelve (12) equal quarterly installments thereafter.